Evidence map›Paper›PMID 27567689›Full record

ArticleUrologic oncology2017

The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.

Brandon J Manley, Daniel M Tennenbaum, Emily A Vertosick, James J Hsieh, Daniel D Sjoberg, Melissa Assel, Nicole E Benfante, Seth A Strope, Eric Kim, Jozefina Casuscelli and 4 more

Open access · greenAbstract read
In one paragraph

Article in Urologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Brandon J ManleyUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Daniel M TennenbaumUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Emily A VertosickDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
James J HsiehDepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Daniel D SjobergDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Melissa AsselDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Nicole E BenfanteUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Seth A StropeDivision of Urology, Department of Surgery, Washington University in St. Louis, St. Louis, MO.
Eric KimDivision of Urology, Department of Surgery, Washington University in St. Louis, St. Louis, MO.
Jozefina CasuscelliUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Maria F BecerraUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Abraham Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: russop@mskcc.org.
Memorial Sloan Kettering Cancer Center · USWashington University in St. Louis · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
UROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA082088
6 · The paper itself

Abstract

purposeTo externally evaluate a preoperative points system and a preoperative nomogram, both created to assess time to death after cytoreductive nephrectomy (CN). MATERIALS AND

methodsWe identified 298 patients who underwent CN at our institution, a tertiary cancer center, between 1989 and 2015. To validate the points system, we compared reported overall survival (OS) for each criterion to observed OS in our cohort. To evaluate the nomogram, we prognosticated risk of death at 6 months after surgery for 280 patients with sufficient follow-up in our cohort and evaluated discrimination using area under the curve (AUC) and calibration. Decision curve analysis was performed to assess clinical utility of the nomogram.

resultsSignificant differences in OS were observed between patients with and without 5 of 7 criteria on univariate analysis: low albumin (P<0.0001), high lactate dehydrogenase (P = 0.002), liver metastasis (P = 0.004), retroperitoneal lymphadenopathy (P = 0.002), and supradiaphragmatic lymphadenopathy (P = 0.019). Discrimination from the preoperative model, predicting death within 6 months of surgery was lower in our cohort (AUC = 0.65, 95% CI: 0.52-0.79) than the original publication (AUC = 0.76). Decision curve analysis demonstrated little benefit for applicability.

conclusionsFive previously defined risk factors are predictive of decreased OS after CN in our cohort. We found lower discrimination using the preoperative model and minimal clinical utility according to decision analysis in our study cohort. These findings suggest the need for improved models to aid patient stratification and consequent treatment choice.

Indexed as

Cytoreduction Surgical ProceduresNephrectomyNomogramsPatient SelectionAgedCarcinoma, Renal CellDecision Support TechniquesDiaphragmFemaleFollow-Up StudiesHumansKidney NeoplasmsLiver NeoplasmsL-Lactate DehydrogenaseLymphatic MetastasisMaleL-Lactate DehydrogenaseSerum AlbuminMortalityNeoplasm metastasisNephrectomyPrognosisRenal cell carcinoma

Identifiers

PMID27567689
PMCPMC5154851
OpenAlexW2518101395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.